- Background
- What we're looking for
- What we can offer you
- Who we are
- Q&A
Pancreatic ductal adenocarcinoma (PDAC) shows the lowest 5-year survival rate among all cancerous tumors.
For this reason, there is an urgent need to improve the overall survival with new chemical modalities as an alternative to antibody drug conjugates (ADCs) technology.
Antibody drug conjugates (ADCs) technology is not ideal for PDAC. ADCs technology enables us to deliver cytotoxic agents selectively to the tumors. However, in PDAC, the extracellular matrix becomes dense and abnormal, creating a physical barrier to the delivery of therapeutic agents, including large molecules like antibodies, to tumor cells.
Thus, Daiichi-Sankyo aims to develop novel chemical derivatives designed to exhibit high levels of TME penetration and selective internalization into pancreatic ductal adenocarcinoma cells.
We are seeking novel chemical derivatives (small molecules or peptides) that can be internalized into a wide range of PDAC cells selectively. We are also interested in screening systems to identify our desired chemical products.
- Small molecules or peptides that exhibit high levels of TME penetration and selective internalization into pancreatic ductal adenocarcinoma cells
- Novel screening system to identify our desired chemical products.
- in vitro data exhibiting the PDAC cell-selective internalization activity of the compounds or peptides
- in vitro data is required, but it would be preferred to have animal/in vivo data as well.
- The compounds or peptides that show specific cell killing activity in PDAC cells without selective internalization activity into the cells are out of scope.
At Daiichi Sankyo, we attach significant importance to working with academic institutions, startups and bioventure companies to discover new therapeutics in the place where hypotheses are brought and tested in order to expand possibilities for scientific innovation breakthrough. We build sustainable relationships with partner institutions and companies through open and fair alliance management and trust based on mutual respect as the foundation for effective collaborations. Our goal is to jointly create new value for patients by maximizing each other’s expertise and strengths.
https://www.daiichisankyo.com/rd/strategy_operations/open_innovation/
Learn moreThe Q&A is now closed.
Other recommended requests
delivered to your inbox.